Showing results (1-10 of 8) with videos related to
Sort By:
Pageof 1
Personalized Medicine|May 23, 2018
Interview: An interview with Lawrence Lesko for Personalized MedicineLawrence LeskoJAMA Network Open|April 25, 2020
Association of Oral Anticoagulants and Verapamil or Diltiazem With Adverse Bleeding Events in Patients With Nonvalvular Atrial Fibrillation and Normal Kidney FunctionPhuong Pham, Stephan Schmidt, Lawrence Lesko, et al.Clinical Pharmacology in Drug Development|October 7, 2020
A Review on Drug-Induced Nephrotoxicity: Pathophysiological Mechanisms, Drug Classes, Clinical Management, and Recent Advances in Mathematical Modeling and Simulation ApproachesHardik Mody, Vidya Ramakrishnan, Maher Chaar, et al.Journal of Pharmaceutical Sciences|November 22, 2023
Identification of Novel and Early Biomarkers for Cisplatin-induced Nephrotoxicity and the Nephroprotective Role of Cimetidine using a Pharmacometabolomic-based Approach Coupled with In Vitro Toxicodynamic Modeling and SimulationHardik Mody, Sreenath Nair, Adrian Rump, et al.Journal of Clinical Pharmacology|May 16, 2019
Physiologically Based Pharmacokinetic Modeling to Evaluate Formulation Factors Influencing Bioequivalence of Metoprolol Extended-Release ProductsSumit Basu, Haitao Yang, Lanyan Fang, et al.Drug Discovery Today|February 8, 2020
Study of pharmacogenomic information in FDA-approved drug labeling to facilitate application of precision medicineDarshan Mehta, Ryley Uber, Taylor Ingle, et al.Annual Review of Pharmacology and Toxicology|October 9, 2020
Model-Informed Precision Dosing: Background, Requirements, Validation, Implementation, and Forward Trajectory of Individualizing Drug TherapyAdam S Darwich, Thomas M Polasek, Jeffrey K Aronson, et al.Nature Reviews. Drug Discovery|June 2, 2010
Voluntary exploratory data submissions to the US FDA and the EMA: experience and impactFederico M Goodsaid, Shashi Amur, Jiri Aubrecht, et al.Pageof 1